Assessment of Endothelial Function, Apolipoproteins and Adiponectin

Completed

Conditions studied: Cirrhosis

In brief

The overall hypothesis is that endothelial function, apolipoprotein levels and adiponectin levels are accurate predictors of underlying cardiovascular disease in patients with end-stage liver disease, in whom standard tools for the diagnosis of and screening for cardiovascular disease are of limited utility.

Key facts

Study ID

NCT01300390

Run by

Mayo Clinic

People needed

150

Starts

2011-06-01

Expected to finish

2015-10-01

Last updated by the study team

2016-05-17

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Greater than or equal to 21 years of age.
• Cirrhotic end-stage liver disease
• Pre-transplant

You may not qualify if…

• Dialysis shunt
• non-cirrhotic liver disease
• fulminant hepatic failure

Where it is running

• Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.